| Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 16446517 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although percutaneous coronary intervention (PCI) following full-dose thrombolytic therapy (rescue angioplasty) is a common procedure, there is ample controversy regarding the usefulness of the procedure. Moreover, few data are available concerning the safety and efficacy of concomitant treatment with glycoprotein (GP) IIb/IIIa inhibitors in these patients. The aim of the present study was to compare the clinical outcomes of patients who underwent rescue PCI with stents and were treated with GP IIb/IIIa inhibitors. A total of 59 consecutive patients underwent rescue PCI at our institution during the study period, 29 patients (49.2%) were treated concomitantly with a GP IIb/IIIa inhibitor and 30 patients (50.8%) were not. Baseline clinical characteristics were similar between the two groups. In-hospital outcomes regarding death, reinfarction and the need for urgent target vessel revascularization was significantly lower in patients treated with GP IIb/IIIa inhibitors compared to those who were not treated (3.4% vs. 26.7%; p = 0.01, respectively). However, GP IIb/IIIa inhibitor administration was not an independent predictor of better outcomes by multivariate analysis. There was a higher rate of major bleeding complications in patients who received GP IIb/IIIa inhibitors, though it did not achieve statistical significance (6.9% vs. 0%; p = 0.14, respectively). The composite endpoint of major, minor bleeding and vascular complications was similar in both groups (24.1% vs. 16.7%; p = 0.48). In conclusion, the administration of GP IIb/IIIa inhibitors in patients undergoing rescue PCI after failed thrombolysis with stents was safe and may have a beneficial effect on 30-day event-free survival rates, without a significant increase in bleeding or vascular complications. These results warrant further investigation. |
| | |
Authors:
|
Luis Gruberg; Mahmoud Suleiman; Michael Kapeliovich; Haim Hammerman; Ehud Grenadier; Monther Boulus; Shlomo Amikam; Walter Markiewicz; Rafael Beyar |
Related Documents
:
|
18927447 - Target lesion revascularization after wingspan: assessment of safety and durability. 20211327 - Relation of proton pump inhibitor use after percutaneous coronary intervention with dru... 11673337 - Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year... 23286687 - Comparison of the rts and iss scores on prediction of survival chances in multiple trau... 18927447 - Target lesion revascularization after wingspan: assessment of safety and durability. 18473097 - A randomized trial of ceftriaxone versus trimethoprim-sulfamethoxazole to prevent ventr... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: The Journal of invasive cardiology Volume: 18 ISSN: 1557-2501 ISO Abbreviation: J Invasive Cardiol Publication Date: 2006 Feb |
Date Detail:
|
Created Date: 2006-01-31 Completed Date: 2006-06-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8917477 Medline TA: J Invasive Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 59-62 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Rambam Medical Center, Bat Galim, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Transluminal, Percutaneous Coronary* Antibodies, Monoclonal / adverse effects, therapeutic use Cohort Studies Female Hemorrhage / chemically induced Humans Immunoglobulin Fab Fragments / adverse effects, therapeutic use Male Middle Aged Myocardial Infarction / therapy* Peptides / adverse effects, therapeutic use Platelet Aggregation Inhibitors / adverse effects, therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors* Retrospective Studies Salvage Therapy* Stents* Survival Analysis Thrombolytic Therapy Treatment Failure Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Peptides; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/eptifibatide; 143653-53-6/abciximab |
| Comments/Corrections | |
Comment In:
|
J Invasive Cardiol. 2006 Feb;18(2):63-4
[PMID:
16446518
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Percutaneous transvenous mitral commissurotomy using metallic commissurotome: long-term follow-up re...
Next Document: Sequential balloon dilatation for combined aortic valvular stenosis and coarctation of the aorta in ...